BOSTON, Jan. 25, 2016 /PRNewswire/ -- Shares in Insys Therapeutics ("Insys" or the "Company") (Nasdaq: INSY) are down over 31% since their opening price on December 3, 2015, following a series of investigative reports issued by the Southern Investigative Reporting Foundation ("SIRF"), entitled "Murder Incorporated".
Today, SIRF posted a new report entitled "The Brotherhood of Thieves: Insys Therapeutics" which details additional efforts taken by "executives at Insys Therapeutics … to pressure its employees to develop new ways to mislead insurance companies into granting coverage to patients prescribed its drug Sybsys, even as the Food and Drug Administration's Office of Criminal Investigations issues a stream of subpoenas to former employees." The SIRF report includes an audio recording of what purports to be Insys executives admitting the use of dishonest techniques in the submission of prescriptions to insurance companies.
If you purchased Insys Therapeutics stock in 2014 or 2015 and have questions about your legal rights, or if you have information relevant to this investigation, please contact either attorney Steven Harte of Block & Leviton at (617) 398-5600 or email@example.com or Jake Walker at (617) 398-5600 or at firstname.lastname@example.org. Confidentiality for any whistleblowers or other persons with information relevant to the investigation is assured.
Block & Leviton is a Boston-based law firm representing investors for violations of securities laws as well as whistleblowing employees who provide information about their employers' violations of law. The firm's lawyers have collectively been prosecuting securities cases on behalf of investors for over 70 years.
This notice may constitute attorney advertising.
SOURCE Block & Leviton LLP